Chemosensitization Effect of Ribociclib, a CDK4/6 Inhibitor, on In Vitro Cervical Cancer

Objective Dysregulation of cell-cycle control mechanisms plays an important role in the development of many cancers, including cervical cancer. After the role of CDK 4/6 in cell cycle control and carcinogenesis was elucidated, CDK 4/6 inhibitors were developed. Ribociclib is a selective CDK4/6 inhibitor, and although its activity has been investigated in several malignancies, its potential role in cervical cancer remains incompletely defined. This study aimed to evaluate the chemosensitizing effects of ribociclib when combined with cisplatin and paclitaxel in a single human papillomavirus type 18 (HPV18)-positive cervical cancer cell line. Material and Methods For the experimental model, only the HPV18-positive human cervical adenocarcinoma-derived HeLa cell line (ATCC CCL-2) was used. Cells were treated for 24 hours with ribociclib (25 µM), cisplatin (100 µM) plus paclitaxel (2 µM), or cisplatin (100 µM) plus paclitaxel (2 µM) plus ribociclib (25 µM). Untreated cells served as controls. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Markers of angiogenesis, proliferation, apoptosis, and metastatic behavior were evaluated by immunocytochemical staining for VEGF, CDK4, CDK6, Ki-67, Bax, Bcl-2, caspase-3, E-cadherin, vimentin, fibronectin, and MMP-9. Results After 24 hours, cell viability was 48% in the cisplatin plus paclitaxel group and 55% in the cisplatin plus paclitaxel plus ribociclib group. Thus, the addition of ribociclib did not further reduce cell viability compared with chemotherapy alone. Addition of ribociclib to chemotherapy significantly reduced Bcl-2, vimentin, and MMP-9 expression and increased caspase-3 expression compared with chemotherapy alone. No significant additional reductions in VEGF or Ki-67, nor significant additional increases in Bax or E-cadherin, were observed with ribociclib. Conclusion In this single-cell-line, 24-hour in vitro model, ribociclib combined with cisplatin and paclitaxel was associated with changes in selected markers of apoptosis and metastatic behavior, despite not producing lower MTT-measured cell viability than chemotherapy alone. These findings constitute hypothesis-generating preclinical evidence and require validation in additional HPV18-positive and other cervical cancer models, in animal studies, and, ultimately, in clinical studies before any translational conclusions can be drawn.

Authors

Institutions

Publication Details

Journal
Journal of Oncological Sciences
Published
2026-11-18
DOI
https://doi.org/10.37047/jos.galenos.2026.2026-6-5
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Chemosensitization Effect of Ribociclib, a CDK4/6 Inhibitor, on In Vitro Cervical Cancer

Hacer Demir, Fatma Fırat, Meltem Baykara, Sena Ece Davarcı
Journal of Oncological Sciences
Advanced Breast Cancer Therapies
article

Chemosensitization Effect of Ribociclib, a CDK4/6 Inhibitor, on In Vitro Cervical Cancer

Hacer Demir, Fatma Fırat, Meltem Baykara, Sena Ece Davarcı
article en

Abstract

Objective Dysregulation of cell-cycle control mechanisms plays an important role in the development of many cancers, including cervical cancer. After the role of CDK 4/6 in cell cycle control and carcinogenesis was elucidated, CDK 4/6 inhibitors were developed. Ribociclib is a selective CDK4/6 inhibitor, and although its activity has been investigated in several malignancies, its potential role in cervical cancer remains incompletely defined. This study aimed to evaluate the chemosensitizing effects of ribociclib when combined with cisplatin and paclitaxel in a single human papillomavirus type 18 (HPV18)-positive cervical cancer cell line. Material and Methods For the experimental model, only the HPV18-positive human cervical adenocarcinoma-derived HeLa cell line (ATCC CCL-2) was used. Cells were treated for 24 hours with ribociclib (25 µM), cisplatin (100 µM) plus paclitaxel (2 µM), or cisplatin (100 µM) plus paclitaxel (2 µM) plus ribociclib (25 µM). Untreated cells served as controls. Cell viability was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Markers of angiogenesis, proliferation, apoptosis, and metastatic behavior were evaluated by immunocytochemical staining for VEGF, CDK4, CDK6, Ki-67, Bax, Bcl-2, caspase-3, E-cadherin, vimentin, fibronectin, and MMP-9. Results After 24 hours, cell viability was 48% in the cisplatin plus paclitaxel group and 55% in the cisplatin plus paclitaxel plus ribociclib group. Thus, the addition of ribociclib did not further reduce cell viability compared with chemotherapy alone. Addition of ribociclib to chemotherapy significantly reduced Bcl-2, vimentin, and MMP-9 expression and increased caspase-3 expression compared with chemotherapy alone. No significant additional reductions in VEGF or Ki-67, nor significant additional increases in Bax or E-cadherin, were observed with ribociclib. Conclusion In this single-cell-line, 24-hour in vitro model, ribociclib combined with cisplatin and paclitaxel was associated with changes in selected markers of apoptosis and metastatic behavior, despite not producing lower MTT-measured cell viability than chemotherapy alone. These findings constitute hypothesis-generating preclinical evidence and require validation in additional HPV18-positive and other cervical cancer models, in animal studies, and, ultimately, in clinical studies before any translational conclusions can be drawn.

Journal of Oncological Sciences
Afyonkarahisar Sağlık Bilimleri Üniversitesi (TR), Afyon Kocatepe University (TR)
Good health and well-being
Advanced Breast Cancer Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon